Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $276.00 to $300.00 in a research note published on Wednesday,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 price objective for the company. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Royal Bank Of Canada lowered their price target on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating for the company in a report on Thursday, October 8th. Finally, Piper Sandler raised their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $292.05.
Get Our Latest Research Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Stock Performance
Shares of Jazz Pharmaceuticals stock opened at $215.98 on Wednesday. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock’s fifty day moving average is $231.96 and its two-hundred day moving average is $216.24. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a market capitalization of $14.02 billion, a PE ratio of 9.00, a price-to-earnings-growth ratio of 0.42 and a beta of 0.37.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter last year, the business posted ($8.25) earnings per share. As a group, analysts expect that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.
Insider Buying and Selling at Jazz Pharmaceuticals
In other news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the transaction, the director owned 345,875 shares in the company, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 100,121 shares of company stock worth $24,855,802. Company insiders own 4.10% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its position in shares of Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the last quarter. Bank of America Corp DE boosted its stake in Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares in the last quarter. Boston Trust Walden Corp grew its position in Jazz Pharmaceuticals by 24.1% during the 1st quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock worth $92,381,000 after purchasing an additional 94,750 shares during the last quarter. Systematic Financial Management LP grew its position in Jazz Pharmaceuticals by 2.6% during the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after purchasing an additional 10,237 shares during the last quarter. Finally, Quantinno Capital Management LP increased its stake in Jazz Pharmaceuticals by 9.7% during the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after purchasing an additional 16,928 shares in the last quarter. 89.14% of the stock is owned by institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Further Reading
- Five stocks we like better than Jazz Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
